AgomAb Therapeutics NV (AGMB) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$7.00

From 52W high−61.56%

Volume79970.00

Market cap$337.35M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$7.00

From 52W high

−61.56%

Volume

79970.00

Market cap

$337.35M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.0x

P/E (TTM)

—

RSI (14)

26.7

MomentumView details →

1D Return

+0.00%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−3.0x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.3x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−47.78%

ROA (TTM)

−40.69%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

−1.59%

EBITDA YoY

—

MomentumView details →

1D Return

+0.00%

YTD Return

—

1Y Return

—

RSI (14)

26.7

vs 50D SMA

−34.97%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

6.52x

Quick Ratio

6.52x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.91

EPS Surprise

−137.55%

Beats (12Q)

0/12

Next Q EPS Est

$1.32

Avg Surprise (4Q)

−72.16%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Next earningsMar 3, 2027 →

Latest newsMore news →

Agomab Therapeutics announced positive topline results from the 48-week open-label extension of the Phase 2a STENOVA trial of ontunisertib in patients with fibrostenosing Crohn's disease, supporting a planned global Phase 2b NOV-ERA study.35d ago

Agomab Therapeutics announced positive Phase 1 results for AGMB-447 in idiopathic pulmonary fibrosis patients and submitted a CTA for the Phase 2 INSPIRIA study, which it intends to initiate before year-end.51d ago

Similar companies

Alector, Inc.ALEC Eikon Therapeutics, Inc. Common StockEIKN Prelude Therapeutics IncorporatedPRLD Galectin Therapeutics Inc.GALT Benitec Biopharma Inc.BNTC X4 Pharmaceuticals, Inc.XFOR Find similar companies →

Latest newsMore news →

Agomab Therapeutics announced positive topline results from the 48-week open-label extension of the Phase 2a STENOVA trial of ontunisertib in patients with fibrostenosing Crohn's disease, supporting a planned global Phase 2b NOV-ERA study.35d ago Agomab Therapeutics announced positive Phase 1 results for AGMB-447 in idiopathic pulmonary fibrosis patients and submitted a CTA for the Phase 2 INSPIRIA study, which it intends to initiate before year-end.51d ago